Drugs to treat attention deficit hyperactivity disorder were linked to a reduced risk of suicidal behavior, substance misuse and criminality in the first research of its kind.

The announcement by President Donald Trump’s administration of the results of a probe into pharmaceutical imports and new sector-specific tariffs ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

Novartis Pharmaceuticals filed a lawsuit against the State of Rhode Island seeking to block the enforcement of a new state ...

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...